Therapy Areas: Cardiovascular
Dr. Reddy's Laboratories Launches Dimethyl Fumarate Delayed-Release Capsules in the US Market
29 September 2020 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) Delayed-Release Capsules, approved by the US Food and Drug Administration (USFDA), the company said.

The Tecfidera brand and generic market had US sales of approximately USD 3.8bn MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Dr. Reddy's Dimethyl Fumarate Delayed-Release Capsules are available in 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.

Dr. Reddy's Laboratories is an integrated pharmaceutical company.

The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's operates in markets across the globe. Major markets include USA, India, Russia and CIS countries, and Europe.


Related Headlines